Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 11/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062804 | 1.00 | L3MBTL1 (0.43) | L3MBTL1TDP1MAPK1SMN1; SMN2APP | |
| SCHEMBL19839514 | 1.00 | L3MBTL1 (0.43) | L3MBTL1TDP1MAPK1SMN1; SMN2APP | |
| SCHEMBL19839538 | 1.00 | L3MBTL1 (0.43) | L3MBTL1TDP1MAPK1SMN1; SMN2APP | |
| SCHEMBL7681801 | 0.99 | L3MBTL1 (0.44) | L3MBTL1TDP1APPCTSDBACE1 | |
| SCHEMBL7478239 | 0.89 | MEN1 (0.34) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL2797900 | 0.87 | L3MBTL1 (0.36) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL2792896 | 0.87 | L3MBTL1 (0.36) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL2793010 | 0.87 | L3MBTL1 (0.36) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL7471671 | 0.86 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL8308654 | 0.86 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576210-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-08-18 | — | — | US | disclosed |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | CHRNE, CHRM1, ADRB1 | L3MBTL1 164/4885TDP1 1418/4885MAPK1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.